But the great prospect is the use of miltefosine, the first oral drug against leishmaniasis, which may lead to suppression of Nrf2 pathway components and some target genes, changing to the pro-inflammatory macrophage profile. This evidence concerns the gene NFE2L2 and leishmaniasis.